The Fight against Poliovirus Is Not Over
Open accessThe DOI matches its Crossref record; 132 of the 137 references it cites were found in a registry or an index; 60 of the 102 sources its claims cite were checked for support.
Abstract
species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3. The launch of the Global Polio Eradication Initiative (GPEI) in 1988 eradicated two of the three serotypes of WPV (WPV2 and WPV3). However, the endemic transmission of WPV1 persists in Afghanistan and Pakistan in 2022. There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV). Between January 2021 and May 2023, a total of 2141 circulating VDPV (cVDPV) cases were reported in 36 countries worldwide. Because of this risk, inactivated poliovirus (IPV) is being used more widely, and attenuated PV2 has been removed from OPV formulations to obtain bivalent OPV (containing only types 1 and 3). In order to avoid the reversion of attenuated OPV strains, the new OPV, which is more stable due to genome-wide modifications, as well as sabin IPV and virus-like particle (VLP) vaccines, is being developed and offers promising solutions for eradicating WP1 and VDPV.
Overview
CoChat Summary
TL;DR
This narrative review summarizes the current epidemiology of wild poliovirus (WPV) and vaccine-derived poliovirus (VDPV) and the vaccine strategies being developed to finish polio eradication. It argues that although WPV2 and WPV3 have been eradicated, WPV1 transmission and cVDPV outbreaks mean the fight against poliovirus is not over.
Key findings
- Two of three WPV serotypes have been eradicated: WPV2 in 2015 and WPV3 in 2019, but endemic WPV1 transmission persisted in Afghanistan and Pakistan in 2022.
- Between January 2021 and May 2023, 2141 cVDPV cases were reported in 36 countries: 269 cVDPV1 cases in 6 countries, 1868 cVDPV2 cases in 35 countries, and 4 cVDPV3 cases in Israel; 1629 were AFP cases and 512 were non-AFP cases, with 1055 environmental samples also positive.
- Reported WPV1 cases included 5 in Afghanistan and Pakistan in 2021 plus 1 in Namibia; in 2022, 2 in Afghanistan, 20 in Pakistan, and 8 in Mozambique; and 1 in Pakistan between January and May 2023.
- New vaccine approaches include nOPV2, with nearly 600 million doses administered in 28 countries, and sIPV mass vaccination in Sichuan, China, which rapidly suppressed cVDPV2 circulation; remdesivir was reported to clear iVDPV from the stool of a 50-year-old patient.
Methods
- Narrative review of poliovirus biology, pathogenesis, diagnosis, vaccines, VDPV emergence, and new eradication strategies.
- Synthesizes published epidemiological reports, WHO/MMWR surveillance data, and clinical trial results; no primary data collection or systematic review methodology is described.
- Main analysis is descriptive and thematic, covering WPV and VDPV epidemiology and candidate vaccines including nOPV2, sIPV, fractional IPV, and virus-like particles.
Limitations
- No explicit limitations section is included; the text notes that eradication remains difficult because of persistent transmission foci and challenges in implementing mass immunization programmes.
- Evident from the text: as a narrative review, it lacks a stated systematic search strategy, inclusion criteria, or quality appraisal, and it relies on cited surveillance reports and trials rather than primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
42 Valid · 1 Not valid · 19 Not checked · 6 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A long-standing disadvantage of using OPVs is that attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract [9,10,11,12,13,14].”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
What the sources say
- Partly supportedcites [9] Jorba, 2019, Update on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019, MMWR Morb. Mortal. Wkly. Rep. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says a novel OPV2 vaccine is designed to reduce the likelihood of reversion to neurovirulence during replication, supporting the core claim about OPV strains. Our copy does not specify that this replication and reversion occur in the intestinal tract. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [10] Blondel, 2008, Evolution génétique du poliovirus: Succès et difficultés de l’éradication de la poliomyélite paralytique [Genetic evolution of poliovirus: Success and difficulties in the eradication of paralytic poliomyelitis], Med. Trop.
- Supportedcites [11] Yeh, 2020, Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence, Cell Host Microbe. source
The Results section, “Characterization of the Shed Viruses” (page unavailable), describes Sabin2 mutations arising during evolution in the human gut and says most vaccinees excrete viruses that have lost an attenuation allele within 14 days. The same section reports that the Sabin2 revertant mutation produced a neurovirulent virus in mice, supporting the stated risk for conventional OPV strains. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] Contreras, 1992, Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract, Biologicals source
- Not checked — no full text of the sourcecites [13] Minor, 2005, Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains, J. Med. Virol. source
- Partly supportedcites [14] Macadam, 2006, Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication, J. Virol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that polio vaccine viruses can regain virulence through changes acquired during replication, supporting the reversion risk. Our copy does not state that this reversion occurs during replication in the intestinal tract; that specific setting appears only in a reference title. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The oral poliovirus vaccine (OPV) has protected millions of children from paralysis by preventing person-to-person transmission of the virus, which is essential for polio eradication [7].”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
What the sources say
- Partly supportedcites [7] Khan, 2018, Progress Toward Polio Eradication-Worldwide, January 2016–March 2018, MMWR Morb. Mortal. Wkly. Rep. sourceExperimental — accuracy not yet measured
The Discussion (page not specified) says that interrupting poliovirus transmission requires vaccinating missed children and maintaining high population immunity. The Supplementary Immunization Activities section documents extensive OPV use, but the paper does not say that OPV protected millions of children from paralysis or establish that specific outcome through prevention of person-to-person transmission. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV).”
§ The Fight against Poliovirus Is Not Over > Abstract
What the sources say
- Supportedcites [9] Jorba, 2019, Update on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019, MMWR Morb. Mortal. Wkly. Rep. source
The paper’s opening section describes OPV as a live, attenuated vaccine and says vaccine-derived strains can cause outbreaks of paralytic poliomyelitis. It also discusses reversion to neurovirulence, supporting the claim’s description of lost attenuation (page not provided in our copy). (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [10] Blondel, 2008, Evolution génétique du poliovirus: Succès et difficultés de l’éradication de la poliomyélite paralytique [Genetic evolution of poliovirus: Success and difficulties in the eradication of paralytic poliomyelitis], Med. Trop.
- Supportedcites [11] Yeh, 2020, Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence, Cell Host Microbe. source
The Results section states that OPV strains can revert to a form that causes paralysis. The Introduction links regained virulence to circulating vaccine-derived polioviruses and reports associated paralytic polio cases. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] Contreras, 1992, Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract, Biologicals source
- Not checked — no full text of the sourcecites [13] Minor, 2005, Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains, J. Med. Virol. source
- Supportedcites [14] Macadam, 2006, Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication, J. Virol. source
The Abstract says existing live-attenuated vaccines can revert to virulence and cause disease. It also reports outbreaks of poliomyelitis caused by viruses derived from Sabin vaccine strains, supporting the claim about vaccine-derived poliovirus. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
§ The Fight against Poliovirus Is Not Over > 3. Paralytic Polio Vaccines and Eradication of WPV
What the sources say
- Partly supportedcites [63] Hird, T.R., and Grassly, N.C. (2012). Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog., 8. sourceExperimental — accuracy not yet measured
The Abstract says IPV does not induce enough intestinal mucosal immunity to reduce the prevalence of fecal shedding after oral challenge. But it calls IPV’s effect on transmission in settings with fecal–oral spread unknown, though likely limited compared with OPV. The Discussion also describes reduced transmission in some European settings, so the unqualified claim that IPV is ineffective at preventing virus spread goes beyond the paper. (LLM, conf=0.88)
- Partly supportedcites [67] Mehndiratta, 2014, Poliomyelitis: Historical facts, epidemiology, and current challenges in eradication, Neurohospitalist sourceExperimental — accuracy not yet measured
Table 1 (Introduction; page unavailable) says IPV provides “No gut immunity,” while the Modes of Transmission section says poliovirus spreads through the fecal-oral route. The paper does not explicitly assess whether IPV is ineffective at preventing virus spread, so that part of the claim is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In March 2022, one case of iVDPV3 was detected in a stool sample from an infant with PID in China [109] (Table 2).”
§ The Fight against Poliovirus Is Not Over > 4. Emergence of Vaccine-Derived Poliovirus Strains
What the sources say
- Supportedcites [109] Yao, 2022, Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder-Chongqing, China, 2022, MMWR Morb. Mortal. Wkly. Rep. source
The report’s ‘What is added by this report?’ section states that type 3 vaccine-derived poliovirus was detected in March 2022 in stool specimens from an infant with PID hospitalized in Chongqing, China. The Discussion identifies the infant as an iVDPV patient. (LLM, conf=0.94)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 17 with their cited sources checked
Create a free account to see all 68 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Fight against Poliovirus Is Not Over > 4. Emergence of Vaccine-Derived Poliovirus Strains
“suggesting that reversion to the attenuated phenotype of Sabin strains occurs with circulation times of 1–4 years”
§ The Fight against Poliovirus Is Not Over > 1. Introduction
“attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract”
Citations
Cites
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703 · cited 1×
“In communities with low vaccination coverage, these pathogenic OPV-derived strains (known as VDPV, vaccine-derived PV) can have the capacity to circulate in these popula-tions, maintain a reservoir of pathogenic strains and cause polio [15,16].”
BackgroundICTV Virus Taxonomy Profile: Picornaviridae
Zell, R., Delwart, E., Gorbalenya, A. E., Hovi, T., King, A. M. Q., Knowles, N. J., Lindberg, A. M., Pallansch, M. A., Palmenberg, A. C., Reuter, G., et al. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000911 · Cited by 631 · cited 3×
“The genome contains a large open reading frame (ORF), flanked by a highly structured 5′ untranslated region (5′ UTR) and a 3′ UTR terminated with a poly(A) tail [17].”
BackgroundInfluentialKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 1×
“Affected patients were either partially vaccinated or unvaccinated [91].”
BackgroundThe life cycle of non-polio enteroviruses and how to target it
Baggen, J., Thibaut, H. J., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0005-4 · Cited by 478
From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed
Nathanson, N., & Kew, O. M. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq320 · Cited by 404 · cited 8×
“Less than 1% of polio cases result in temporary or permanent acute flaccid paralysis (AFP) [22].”
BackgroundInfluentialOne hundred years of poliovirus pathogenesis
Racaniello, V. R. (2006) · Virology · doi:10.1016/j.virol.2005.09.015 · Cited by 322 · cited 1×
“PV has a limited host range, and humans are the only natural reservoir [20,21].”
BackgroundBurns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276 · cited 1×
“OPV confers passive immunity to unvaccinated individuals through the attenuated vaccine strains shed in the feces of vaccinated individuals [65].”
BackgroundEmerging Concept of Poliomyelitis Infection
Bodian, D. (1955) · Science · doi:10.1126/science.122.3159.105 · Cited by 251 · cited 1×
“After infection, the virus first replicates in the pharynx and small intestine, particularly in the lymphoid tissues (tonsils and Peyer’s patches) [26].”
BackgroundMucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Research works printed but not linked: 1
- Knipe, D.M., and Howley, P.M. (2007). Fields Virology, Lippincott Williams and Wilkins.
Cited by
The Glucans Mushrooms: Molecules of Significant Biological and Medicinal Value
Flores, G. A., Cusumano, G., Venanzoni, R., & Angelini, P. (2024) · Polysaccharides · doi:10.3390/polysaccharides5030016 · Cited by 47
“This antiviral action is believed to involve increased interferon-gamma release and enhanced PBMC proliferation [75,76].”
Chatterjee, S., Kordbacheh, R., & Sin, J. (2024) · Microorganisms · doi:10.3390/microorganisms12020274 · Cited by 26
Structural Virology: The Key Determinants in Development of Antiviral Therapeutics
Handa, T., Saha, A., Narayanan, A., Ronzier, E., Kumar, P., Singla, J., & Tomar, S. (2025) · Viruses · doi:10.3390/v17030417 · Cited by 17
“…Orthomyxoviridae (e.g., influenza viruses) [17,18], Herpesviridae (e.g., herpes simplex virus-HSV) [22–25], Papillomaviridae (e.g., human papillomavirus-HPV) [26–28], Retroviridae (e.g., human immunodeficiency virus-HIV-1 and HIV-2) [29,30], and Picornaviridae (e.g., poliovirus) families [31,32].”
Eze, O. V., Meyer, J. C., & Campbell, S. (2025) · Vaccines · doi:10.3390/vaccines13030232 · Cited by 20
“The infection was linked to the type 2 variant detected earlier in environmental samples collected from Gaza wastewater, with poor sanitation resulting in poliovirus typically spreading through the fecal–oral route in unsanitary environments [15,23,24].”
Enterovirus Antibodies: Friends and Foes
Mbani, C. J., Morvan, C., Nekoua, M. P., Debuysschere, C., Alidjinou, E. K., Moukassa, D., & Hober, D. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.70004 · Cited by 9
“In recent years, native antigenic PV VLPs have been produced using various systems such as mammalian cells, plants, insects, bacteria, and yeast [83].”
InfluentialSelf-citation
Metadata
- Authors
- Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D.
- Affiliations
- Université de Lille (FR)
- Marien Ngouabi University (CG)
- Corresponding author
- Hober, Didier
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2023-05-17
- Volume
- 11
- Issue
- 5
- Pages
- 1323
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC10220725
- OpenAlex
- W4377103213
- Cited by
- 34
- References
- 137
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
- Funders
- Ministère de l’Education Nationale de la Recherche et de la Technologie (ULR3610, 130771P)
- “SSHN JEUNE CHERCHEUR” scholarship of Ministère de l’Europe et des Affaires Etrangères and by Campus France (ULR3610, 130771P)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- poliovirus, wild poliovirus type 1, vaccine-derived poliovirus, oral polio vaccine, inactivated poliovirus vaccine, bivalent oral poliovirus vaccine, virus-like particle vaccine, polio eradication, paralytic poliomyelitis, Global Polio Eradication Initiative
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Fight against Poliovirus Is Not Over. https://app.cochat.ai/papers/10.3390/microorganisms11051323
- The paper
- Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023). The Fight against Poliovirus Is Not Over. Microorganisms. https://doi.org/10.3390/microorganisms11051323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.